Neomatrix is a biotechnology company developing next-generation personalized cancer vaccines designed to rapidly target tumor-specific neoantigens and prevent tumor relapse. Our proprietary synthetic DNA platform has demonstrated potent immune and antitumor activity in preclinical animal models (*). Toxicology and biodistribution studies have been successfully completed, supporting the clinical development of our lead candidate in Non-Small Cell Lung Cancer (NSCLC).The combination of fully synthetic DNA technology and electroporation delivery (**) is designed to enable a rapid turnaround time and scalable manufacturing process compatible with personalized phase I-II clinical studies.
